Navigation Links
Symphony Corporation Acquires JGI to Provide End-to-End Services for Healthcare IT
Date:8/8/2011

n the new role of Senior Vice President of Sales and Business Development for Symphony.

JGI brand products and services will be under the Symphony Corporation brand, for more information visit www.symphonycorp.com

About Symphony Corporation

Symphony Corporation is a Madison, Wisconsin based global technology solutions provider that helps organizations develop and implement a range of technology solutions in less time at a lower cost.  Symphony's commitment to quality processes such as CMMi Level 4 has brought it to an industry leadership position in specialized IT services. Symphony maintains world-class development facilities that are audited and comply with HIPAA and FDA CFR guidelines.  Symphony has more than 13 years of experience in developing and managing transaction based enterprise applications and large data warehouses to web and mobile applications. Clients include large health systems, medical devices manufacturers, and Fortune 500 companies. Specific to the healthcare industry, Symphony has extensive experience in implementation and integration of clinical systems, healthcare informatics, as well as quality and care management systems.


'/>"/>
SOURCE Symphony Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Echo Therapeutics Announces Symphony™ tCGM System Progress
2. ImpactRx Acquired by Symphony Technology Group
3. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
4. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
5. Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System
6. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
7. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
8. Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
(Date:9/22/2014)... 2014 CytRx Corporation (Nasdaq: CYTR ... oncology, today announced that study designs and progress from ... a pivotal global Phase 3 clinical trial in relapsed/refractory ... clinical trial in small cell lung cancer, will be ... 2014 Congress being held September 26-30, in ...
(Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
(Date:9/22/2014)... of Naval Research (ONR) this week is showcasing a ... will prepare Marines as they continue to face an ... be in Booth No. 2305 during the event, held ... how their research contributes to the expeditionary ethos of ... ONR,s Expeditionary Maneuver Warfare and Combating Terrorism Department, the ...
(Date:9/22/2014)... Follow us on LinkedIn ... presence in the medical field, as respiratory dysfunction ... Key factors underlying the rise in respiratory diseases ... increasing levels of air pollution and rise in ... population vulnerable to respiratory problems. Demand for respiratory ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Colorado's grand ... draw international attention, while piling up unprecedented revenue for ... about $90 million worth of recreational cannabis was sold ... 2014, the first year of such sales. , But ... some issues, when it comes to handling the thousands ...
(Date:9/22/2014)... be released from prison need to be more involved ... reintegrate into their communities and avoid returning to prison, ... all female prisoners are back behind bars within one ... terms, mainly for drug-related offenses. , Dr. Flora Matheson, ... with women who were about to be released or ...
(Date:9/22/2014)... be an old acquaintance: a certain module of the ... an anchor protein. The researchers report their findings in ... enzymes into peroxisome , Peroxisomes are of vital ... and cellular toxins. In order for them to fulfil ... into the peroxisomes first. The bulk is brought into ...
Breaking Medicine News(10 mins):Health News:Modern Day Marine: ONR features technology for marines of the future 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 3Health News:Involving female offenders in release planning can increase reintegration success 2Health News:The accelerator of molecular motors 2
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... receive fewer blood transfusions do just as well as those ... of blood transfusions varies widely among U.S. hospitals. The ... Journal of the American Medical Association . In ...
... murine leukemia virusrelated virus (XMRV) has been the subject ... conflicting reports have created an unclear picture of XMRV,s ... in the November 15 issue of The Journal ... supports a possible link between XMRV and prostate cancer ...
... molecule they designed can block activation of a gene in ... those cancer cells to survive chemotherapy. Without the ... to be protected from the toxic effects of chemotherapy drugs. ... protecting the cells, the research suggests. As a result, more ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Oct. ... cancer patients treated with bisphosphonate drugs such as Aredia or ... be at higher risk for the irregular heartbeat known as ... atrial fibrillation, the upper chambers of the heart beat chaotically, ...
... results of a large Phase-III clinical trial have shown ... with a hard-to-treat group of rare cancers that affect ... the European Society for Medical Oncology (ESMO), Dr Marianne ... everolimus improved progression-free survival by 5.1 months in patients ...
... of breast cancer can lead some women to wonder if ... of more than 85,000 postmenopausal women, published in BioMed Central,s ... regular physical activity, maintaining a healthy weight, and drinking less ... a family history of the disease. The University of ...
Cached Medicine News:Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 2Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
... ChartingPlus proves itself to over 2,000 medical ... with the user in mind, ChartingPlus relies ... and dynamic features to improve documentation quality ... Our medical content is specific ...
Medicine Products: